Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3204139rdf:typepubmed:Citationlld:pubmed
pubmed-article:3204139lifeskim:mentionsumls-concept:C0008550lld:lifeskim
pubmed-article:3204139lifeskim:mentionsumls-concept:C0070357lld:lifeskim
pubmed-article:3204139pubmed:dateCreated1989-2-7lld:pubmed
pubmed-article:3204139pubmed:abstractText[D-Ala1]peptide T amide is a metabolically stable and more potent analogue of peptide T, a proposed inhibitor of human immunodeficiency viral infectivity of human T-cell lymphocytes. The peptide was synthesized by solid-phase methods to provide amounts of several grams. The product was purified by chromatography on a 25 cm x 2 in. column of DuPont Zorbax Pro-10 C8 (10 micron) packing. Sample loads of 100-450 mg were chromatographed isocratically in 0.1% trifluoroacetic acid and 5% acetonitrile at a flow-rate of 110 ml/min. Under these conditions, the pure peptide fraction was eluted reproducibly between 15 and 22 min. After solvent removal and lyophilization, the recovery of pure peptide was 50% by weight.lld:pubmed
pubmed-article:3204139pubmed:languageenglld:pubmed
pubmed-article:3204139pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3204139pubmed:citationSubsetIMlld:pubmed
pubmed-article:3204139pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3204139pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3204139pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3204139pubmed:statusMEDLINElld:pubmed
pubmed-article:3204139pubmed:monthJullld:pubmed
pubmed-article:3204139pubmed:issn0021-9673lld:pubmed
pubmed-article:3204139pubmed:authorpubmed-author:KnightMMlld:pubmed
pubmed-article:3204139pubmed:authorpubmed-author:PerkinsRRlld:pubmed
pubmed-article:3204139pubmed:authorpubmed-author:BurkeT RTRJrlld:pubmed
pubmed-article:3204139pubmed:authorpubmed-author:MackG DGDlld:pubmed
pubmed-article:3204139pubmed:issnTypePrintlld:pubmed
pubmed-article:3204139pubmed:day1lld:pubmed
pubmed-article:3204139pubmed:volume444lld:pubmed
pubmed-article:3204139pubmed:ownerNLMlld:pubmed
pubmed-article:3204139pubmed:authorsCompleteYlld:pubmed
pubmed-article:3204139pubmed:pagination345-8lld:pubmed
pubmed-article:3204139pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3204139pubmed:meshHeadingpubmed-meshheading:3204139-...lld:pubmed
pubmed-article:3204139pubmed:meshHeadingpubmed-meshheading:3204139-...lld:pubmed
pubmed-article:3204139pubmed:meshHeadingpubmed-meshheading:3204139-...lld:pubmed
pubmed-article:3204139pubmed:meshHeadingpubmed-meshheading:3204139-...lld:pubmed
pubmed-article:3204139pubmed:meshHeadingpubmed-meshheading:3204139-...lld:pubmed
pubmed-article:3204139pubmed:year1988lld:pubmed
pubmed-article:3204139pubmed:articleTitleReversed-phase preparative chromatography of [D-Ala1]-peptide T amide.lld:pubmed
pubmed-article:3204139pubmed:affiliationPeptide Technologies Corporation, Trinity College, Washington, DC 20017.lld:pubmed
pubmed-article:3204139pubmed:publicationTypeJournal Articlelld:pubmed